Holen Sie sich die Stockscreener-App
6.00
30.15%
1.39
Handel nachbörslich:
6.70
0.70
+11.67%
Schlusskurs vom Vortag:
$4.61
Offen:
$4.62
24-Stunden-Volumen:
165.18K
Relative Volume:
0.01
Marktkapitalisierung:
$4.62M
Einnahmen:
$40,400
Nettoeinkommen (Verlust:
$-9.18M
KGV:
-22.35
EPS:
-0.2684
Netto-Cashflow:
$-5.78M
1W Leistung:
+7,889%
1M Leistung:
+3,202%
6M Leistung:
+938.24%
1J Leistung:
+383.87%
1-Tages-Spanne:
$4.62
$6.10
1-Wochen-Bereich:
$4.56
$6.10
52-Wochen-Spanne:
$0.071
$6.10
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Firmenname
Jupiter Neurosciences Inc
Sektor
Branche
Telefon
(561) 406-6154
Adresse
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
6.00 | 3.55M | 40,400 | -9.18M | -5.78M | -0.2684 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jupiter Neurosciences Inc Aktie (JUNS) Neueste Nachrichten
Jupiter Neurosciences Stock Short Interest Falls to 34.91% - Quiver Quantitative
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
Stock Splits Calendar for: - Yahoo! Finance Canada
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance - Minichart
Jupiter Neurosciences Enacts 1-for-75 Reverse Stock Split - TipRanks
Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com - Investing.com UK
Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading - Stock Titan
Jupiter Neurosciences executes 1-for-75 reverse stock split - Investing.com
Jupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026 - Quiver Quantitative
Jupiter Neurosciences, Inc. Announces Reverse Stock Split - GlobeNewswire
Jupiter Neurosciences announces 1-for-75 revers... - Pluang
Kaskela Law Firm Announces Stockholder Investigation of Jupiter N - The National Law Review
Jupiter Neurosciences expands into psychedelics with $100m deal - Longevity.Technology
Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA - Stock Titan
Jupiter Neurosciences Inc (JUNS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jupiter Neurosciences Stockholders Approve Key 2026 Actions - TipRanks
Jupiter Neurosciences, Inc. Files Form 8-K: Key Details on Nasdaq Listing, Address, and Corporate Status - Minichart
Jupiter Neurosciences (NASDAQ: JUNS) details Yorkville SEPA terms - Stock Titan
Jupiter Neurosciences Inc (JUNS) Cash Flow - TradingKey
Jupiter Neurosciences Inc (JUNS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jupiter Neurosciences Inc (JUNS) Balance Sheet - TradingKey
Jupiter Neurosciences, Inc. Revenue Breakdown – NASDAQ:JUNS - TradingView
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout | AI
Jupiter Neurosciences Inc (JUNS) Institutional Confidence - TradingKey
Jupiter Neurosciences Expands CNS Pipeline with $100M ALA-002 Licensing DealEPS Surprise History - dars.gov.et
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences - TipRanks
Jupiter Neurosciences licenses MDMA drug in deal worth up to $100M - Dealroom
JUNS|Jupiter Neurosciences Inc|Price:0.148|Chg%:-0.005 - TradingKey
Jupiter Neurosciences director Andrew Jon Cutler files initial beneficial ownership statement - Bitget
Jupiter Neurosciences Secures Exclusive US Rights for ALA-002 - sekbernews.id
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva - Yahoo Finance
CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech - Mugglehead Investment Magazine
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 - EIN Presswire
Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M - MSN
Jupiter Neurosciences licenses MDMA drug ALA-002 - BioXconomy
PharmAla Biotech Licenses Lead Candidate ALA-002 to Jupiter Neuroscience in the US - Moomoo
Jupiter Neurosciences signs ALA-002 license agreement worth up to $100 million (NASDAQ:JUNS) - MSN
Jupiter Neurosciences expands CNS pipeline with $100 million PharmAla MDMA deal - The Pharma Letter
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 - Investing News Network
Jupiter Neurosciences Licenses ALA-002 for U.S. Development - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Jupiter Neurosciences (Nasdaq: JUNS) to license ALA-002 in US - Stock Titan
Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal - TipRanks
Jupiter Neurosciences (NASDAQ:JUNS) surge cools as $100 million MDMA agreement strains funding resources - TechStock²
Tuesday's session: most active stocks - ChartMill
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) - Yahoo Finance
Jupiter enters psychedelics space with $100M deal for MDMA drug - Fierce Biotech
PharmAla Biotech Grants Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 in $100M Licensing Deal - Kalkine Media
Finanzdaten der Jupiter Neurosciences Inc-Aktie (JUNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):